Appendix Neoplasm

cancer family

Identifier: CI-CAN-00000067
Entity page: /cancer/appendix-neoplasm ↗
Edges: 120

Neighbours: 6 genes19 drugs10 trials
Drawn: 35 of 35 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Appendix Neoplasm investigated for …INVESTIGATED_FOR7 of 7
← investigated for	Thalidomidesmall_molecule	unknown	2	Appendix Neoplasm	1	Curated	chembl	graph →
← investigated for	Nintedanibsmall_molecule	unknown	2

Appendix Neoplasm altered in cohorts of …ALTERED_INderived6 of 6
← altered in cohorts of	KRAS 161 / 273 cases (59 %) · ssm · appendiceal_msk_2022	—	—	Appendix Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	GNAS 91 / 273 cases (33 %) · ssm · appendiceal_msk_2022	—	—	Appendix Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	TP53 86 / 273 cases (32 %) · ssm · appendiceal_msk_2022	—	—	Appendix Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	SMAD4 35 / 273 cases (13 %) · ssm · appendiceal_msk_2022	—	—	Appendix Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	PIK3CA 26 / 273 cases (9.5 %) · ssm · appendiceal_msk_2022	—	—	Appendix Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	SOX9 21 / 273 cases (7.7 %) · ssm · appendiceal_msk_2022	—	—	Appendix Adenocarcinoma	1	Observed	cbioportal	graph →

Appendix Neoplasm altered in cohorts of …ALTERED_INderived6 of 6

← altered in cohorts of

KRAS

161 / 273 cases (59 %) · ssm · appendiceal_msk_2022

—

Appendix Adenocarcinoma

Observed

Appendix Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 27show all (up to 200)
→ investigated in trials for	Mitomycinsmall_molecule 8 trials (3 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 8 trials (3 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall_molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall_molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cobimetinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Appendix Neoplasm	1	Observed	clinicaltrials	graph →

Appendix Neoplasm studied in …STUDIED_INderived10 of 80show all (up to 200)
→ studied in	NCT07060014Phase 1 · recruiting NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers · condition mapped ALIAS · 80 trials mapped (36 active)	—	—	Malignant Appendix Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07271355Phase 3 · recruiting Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial · condition mapped CURATED_BROADER · 80 trials mapped (36 active)	—	—	Appendix Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06263088NA · recruiting EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. · condition mapped ALIAS · 80 trials mapped (36 active)	—	—	Malignant Appendix Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03074513Phase 2 · active not recruiting Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors · condition mapped ONTOLOGY_EXACT · 80 trials mapped (36 active)	—	—	Appendix Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07283939NA · recruiting Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays · condition mapped ONTOLOGY_EXACT · 80 trials mapped (36 active)	—	—	Appendix Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07795749Phase 2 · recruiting Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) · condition mapped ALIAS · 80 trials mapped (36 active)	—	—	Appendix Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07658196Phase 1 · recruiting TLR9 Immunotherapy for Peritoneal Carcinomatosis · condition mapped ALIAS · 80 trials mapped (36 active)	—	—	Appendix Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07753824Phase 2 · not yet recruiting A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) · condition mapped ALIAS · 80 trials mapped (36 active)	—	—	Appendix Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04329494Phase 1 · recruiting PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer · condition mapped CURATED_BROADER · 80 trials mapped (36 active)	—	—	Appendix Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04847063Phase 1 · recruiting Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies · condition mapped ALIAS · 80 trials mapped (36 active)	—	—	Malignant Appendix Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains